Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 31;12(11):1241.
doi: 10.3390/v12111241.

HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection

Affiliations

HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection

Louisa A Carlisle et al. Viruses. .

Abstract

HIV-1 genetic diversity can be used to infer time since infection (TSI) and infection recency. We adapted this approach for HCV and identified genomic regions with informative diversity. We included 72 HCV/HIV-1 coinfected participants of the Swiss HIV Cohort Study, for whom reliable estimates of infection date and viral sequences were available. Average pairwise diversity (APD) was calculated over each codon position for the entire open reading frame of HCV. Utilizing cross validation, we evaluated the correlation of APD with TSI, and its ability to infer TSI via a linear model. We additionally studied the ability of diversity to classify infections as recent (infected for <1 year) or chronic, using receiver-operator-characteristic area under the curve (ROC-AUC) in 50 patients whose infection could be unambiguously classified as either recent or chronic. Measuring HCV diversity over third or all codon positions gave similar performances, and notable improvement over first or second codon positions. APD calculated over the entire genome enabled classification of infection recency (ROC-AUC = 0.76). Additionally, APD correlated with TSI (R2 = 0.33) and could predict TSI (mean absolute error = 1.67 years). Restricting the region over which APD was calculated to E2-NS2 further improved accuracy (ROC-AUC = 0.85, R2 = 0.54, mean absolute error = 1.38 years). Genetic diversity in HCV correlates with TSI and is a proxy for infection recency and TSI, even several years post-infection.

Keywords: genetic variation; hepatitis C virus infection; infection recency; sequence analysis; viral genomics.

PubMed Disclaimer

Conflict of interest statement

HFG has received unrestricted research grants from Gilead Sciences and Roche; fees for data and safety monitoring board membership from Merck; and consulting/advisory board membership fees from Gilead Sciences, Sandoz and Mepha. EB has received fees for his institution for participation to advisory board from MSD, Gilead Sciences, ViiV Healthcare, Sandoz, Pfizer, Abbvie and Janssen. MC has received research and travel grants for his institution from ViiV and Gilead. AR reports support to his institution for advisory boards and/or travel grants from Janssen-Cilag, MSD, Gilead Sciences, Abbvie, and Bristol-Myers Squibb, and an unrestricted research grant from Gilead Sciences. All remuneration went to his home institution and not to AR personally, and all remuneration was provided outside the submitted work. KJM has received travel grants and honoraria from Gilead Sciences, Roche Diagnostics, GlaxoSmithKline, Merck Sharp & Dohme, Bristol-Myers Squibb, ViiV and Abbott; and the University of Zurich received research grants from Gilead Science, Roche, and Merck Sharp & Dohme for studies that Metzner serves as principal investigator, and advisory board honoraria from Gilead Sciences. RDK has received honoraria from Gilead Sciences (unrelated to the current work). JB received fees for his institution from Roche Glycart AG for consulting unrelated to the current work. DLB has received consulting/advisory board honoraria from Gilead Sciences, ViiV, and Merck Sharp & Dohme. MS received educational grants from Janssen-Cilag, MSD and Gilead, and Advisory Board fees from MSD, Gilead, AbbVie, ViiV, Sandoz and Mepha.

Figures

Figure 1
Figure 1
Average pairwise diversity (APD) against time since infection for APD calculated over each of the codon positions in turn, and over all three codon positions. Linear regression models are shown as solid lines.
Figure 2
Figure 2
Receiver operator characteristics (ROC) curves comparing the ability of average pairwise diversity (APD) calculated over each and all codon positions to infer whether infections are recent (<1 year post-infection) or chronic. APD was calculated across the whole HCV open reading frame. All 50 patients who could be clearly classified as recent or chronic are included. Recent infection is taken as the positive outcome. AUC = area under the ROC curve.
Figure 3
Figure 3
Area under the ROC curve, R2, and mean absolute error across the HCV open reading frame, all codon positions. The HCV open reading frame was split into 11 overlapping regions of approximately 500 amino acid codons, and average pairwise diversity (APD) was calculated over individual regions, using all codon positions. Regions were tested for their ability to categorize infection as recent (<1 year) or chronic (top), their correlation with time since infection (middle), and their ability to infer time since infection (bottom). Black dashed lines show the respective values for APD calculated over the whole open reading frame. A similar analysis was performed with diversity calculated over each gene in turn. The HCV genome is shown along the x-axis, with genes colour-coded for a composite (z-score sum, see Supplementary Equation S1) of all three outcome scores. Darker red indicates a better overall performance. Numbers along the x-axis refer to amino acid positions of the H77 reference genome.
Figure 4
Figure 4
Time since infection against estimated time since infection as calculated from average pairwise diversity (APD). APD calculated over the recommended region of amino acid codons 503–1004 (left), and the recommended genes E2, p7, and NS2 (right).

Similar articles

Cited by

References

    1. Wedemeyer H., Duberg A.S., Buti M., Rosenberg W.M., Frankova S., Esmat G., Ormeci N., Van Vlierberghe H., Gschwantler M., Akarca U., et al. Strategies to manage hepatitis C virus (HCV) disease burden. J. Viral Hepat. 2014;21:60–89. doi: 10.1111/jvh.12249. - DOI - PubMed
    1. Armstrong G.L., Alter M.J., McQuillan G.M., Margolis H.S. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777–782. doi: 10.1002/hep.510310332. - DOI - PubMed
    1. Cotte L., Cua E., Reynes J., Raffi F., Rey D., Delobel P., Gagneux-Brunon A., Jacomet C., Palich R., Laroche H., et al. Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. Liver Int. 2018;38:1736–1740. doi: 10.1111/liv.13922. - DOI - PubMed
    1. Ghosn J., Deveau C., Goujard C., Garrigue I., Saichi N., Galimand J., Nagy Z., Rouzioux C., Meyer L., Chaix M.-L., et al. Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection. Sex. Transm. Infect. 2006;82:458–460. doi: 10.1136/sti.2006.021493. - DOI - PMC - PubMed
    1. Giuliani M., Caprilli F., Gentili G., Maini A., Lepri A.C., Prignano G., Palamara G., Giglio A., Crescimbeni E., Rezza G. Incidence and Determinants of Hepatitis C Virus Infection Among Individuals at Risk of Sexually Transmitted Diseases Attending a Human Immunodeficiency Virus Type 1 Testing Program. Sex. Transm. Dis. 1997;24:533–537. doi: 10.1097/00007435-199710000-00007. - DOI - PubMed

Publication types